



Novel diagnostic tool for prediction of variant spliceogenicity derived from a set of 395 combined in silico/in vitro studies: an international collaborative effort

Raphael Leman, Pascaline Gaildrat, Gerald L. Gac, Chandran Ka, Yann Fichou, Marie-Pierre Audrezet, Virginie Caux-Moncoutier, Sandrine M. Caputo, Nadia Boutry-Kryza, Melanie Leone, et al.

► To cite this version:

Raphael Leman, Pascaline Gaildrat, Gerald L. Gac, Chandran Ka, Yann Fichou, et al.. Novel diagnostic tool for prediction of variant spliceogenicity derived from a set of 395 combined in silico/in vitro studies: an international collaborative effort. *Nucleic Acids Research*, 2018, 46 (15), pp.7913-7923. 10.1093/nar/gky372 . hal-01910334

HAL Id: hal-01910334

<https://hal.science/hal-01910334>

Submitted on 25 Jul 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Novel diagnostic tool for prediction of variant spliceogenicity derived from a set of 395 combined *in silico/in vitro* studies: an international collaborative effort

Raphaël Leman^{1,2,3,†,§}, Pascaline Gaildrat^{2,†,§}, Gérald L. Gac⁴, Chandran Ka⁴, Yann Fichou⁴, Marie-Pierre Audrezet⁴, Virginie Caux-Moncoutier^{5,6,7,§}, Sandrine M. Caputo^{7,†,§}, Nadia Boutry-Kryza^{8,§}, Mélanie Léone^{8,§}, Sylvie Mazoyer^{9,†,§}, Françoise Bonnet-Dorion^{10,§}, Nicolas Sevenet^{10,§}, Marine Guillaud-Bataille^{11,§}, Etienne Rouleau^{11,§}, Brigitte Bressac-de Paillerets^{11,§}, Barbara Wappenschmidt^{12,†}, Maria Rössing^{13,†}, Danielle Muller^{14,§}, Violaine Bourdon^{15,§}, Françoise Revillon^{16,§}, Michael T. Parsons^{17,†}, Antoine Rousselin^{1,2,§}, Grégoire Davy^{1,2,§}, Gaia Castelain^{2,§}, Laurent Castéra^{1,2,§}, Joanna Sokolowska^{18,§}, Florence Coulet^{19,§}, Capucine Delnatte^{20,§}, Claude Férec⁴, Amanda B. Spurdle^{17,†}, Alexandra Martins^{2,†,§}, Sophie Krieger^{1,2,3,*†,§} and Claude Houdayer^{5,6,7,*†,§}

¹Laboratoire de Biologie Clinique et Oncologique, Centre François Baclesse, 14000 Caen, France, ²Inserm U1245 Genomics and Personalized Medicine in Cancer and Neurological Disorders, Normandie Univ, UNIROUEN, Normandy Centre for Genomic and Personalized Medicine, 76031 Rouen, France, ³Normandie Univ, UNICAEN, 14000 Caen, France, ⁴Inserm UMR1078, Genetics, Functional Genomics and Biotechnology, Université de Bretagne Occidentale, 29200 Brest, France, ⁵Inserm U830, Institut Curie Centre de Recherches, 75005 Paris, France, ⁶Université Paris Descartes, Sorbonne Paris Cité, 75005 Paris, France, ⁷Service de Génétique, Institut Curie, 75005 Paris, France, ⁸Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon, 69000 Lyon, France, ⁹Lyon Neuroscience Research Center–CRNL, Inserm U1028, CNRS UMR 5292, University of Lyon, 69008 Lyon, France, ¹⁰Inserm U916, Département de Pathologie, Laboratoire de Génétique Constitutionnelle, Institut Bergonié, 33000 Bordeaux, France, ¹¹Gustave Roussy, Université Paris-Saclay, Département de Biopathologie, 94805 Villejuif, France, ¹²Division of Molecular Gynaeco-Oncology, Department of Gynaecology and Obstetrics, University Hospital of Cologne, 50937 Cologne, Germany, ¹³Centre for Genomic Medicine, Rigshospitalet, University of Copenhagen, 1017 Copenhagen, Denmark, ¹⁴Laboratoire d'Oncogénétique, Centre Paul Strauss, 67000 Strasbourg, France, ¹⁵Laboratoire d'Oncogénétique Moléculaire, Institut Paoli-Calmettes, 13009 Marseille, France, ¹⁶Laboratoire d'Oncogénétique Moléculaire Humaine, Centre Oscar Lambret, 59000 Lille, France, ¹⁷Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, 4006 Herston, Queensland, Australia, ¹⁸Service de Génétique, CHU Nancy, 54035 Nancy, France, ¹⁹Service de génétique, Hôpital Pitié Salpêtrière, AP-HP, 75013 Paris, France and ²⁰Laboratoire de génétique moléculaire, CHU Nantes, 44000 Nantes, France

Received February 14, 2018; Revised April 23, 2018; Editorial Decision April 24, 2018; Accepted April 27, 2018

*To whom correspondence should be addressed. Tel: +332455054; Fax: +332455053; Email: s.krieger@baclesse.fr
Correspondence may also be addressed to Claude Houdayer. Tel: +33156245837; Fax: +33153102648; Email: claud.houdayer@curie.fr

†The authors wish it to be known that, in their opinion, the last two authors should be regarded as Joint Last Authors.

§Ucancer Genetic Group (UGG) Splice Network.

†ENIGMA.

Present Addresses:

Sophie Krieger, Laboratoire de biologie et génétique des cancers, Centre François Baclesse, Caen, France.

Claude Houdayer, Service de Génétique, Institut Curie, Paris, France.

ABSTRACT

Variant interpretation is the key issue in molecular diagnosis. Spliceogenic variants exemplify this issue as each nucleotide variant can be deleterious via disruption or creation of splice site consensus sequences. Consequently, reliable *in silico* prediction of variant spliceogenicity would be a major improvement. Thanks to an international effort, a set of 395 variants studied at the mRNA level and occurring in 5' and 3' consensus regions (defined as the 11 and 14 bases surrounding the exon/intron junction, respectively) was collected for 11 different genes, including *BRCA1*, *BRCA2*, *CFTR* and *RHD*, and used to train and validate a new prediction protocol named Splicing Prediction in Consensus Elements (SPiCE). SPiCE combines *in silico* predictions from SpliceSiteFinder-like and MaxEntScan and uses logistic regression to define optimal decision thresholds. It revealed an unprecedented sensitivity and specificity of 99.5 and 95.2%, respectively, and the impact on splicing was correctly predicted for 98.8% of variants. We therefore propose SPiCE as the new tool for predicting variant spliceogenicity. It could be easily implemented in any diagnostic laboratory as a routine decision making tool to help geneticists to face the deluge of variants in the next-generation sequencing era. SPiCE is accessible at (<https://sourceforge.net/projects/spicev2-1/>).

INTRODUCTION

Since the advent of genome wide sequencing, interpretation of variants of unknown significance (VUS) has been recognized as the major bottleneck and challenge for clinical geneticists. Variants are usually classed within a 5-tiered scheme (1) from benign and likely benign variants (class 1 and 2, respectively) to likely pathogenic and pathogenic variants (class 4 and 5, respectively). The geneticist is on relatively solid ground in these four classes, where the biological impact is known or at least likely known. However, class 3 refers to the so called VUS where the effect of the sequence variation on the transcript and protein and thereby on the patient is simply not known. Clinical management logically stems from this knowledge (2) which is why variant classification is of utmost importance.

Hereditary breast and ovarian cancers are mainly due to *BRCA1* (MIM #113705) and *BRCA2* (MIM #600185) pathogenic variants. The *BRCA* genes embody the problem of variant interpretation due to their wide mutational spectrum, which is mostly devoid of specific hot spots. To exemplify this issue, over 30% of the variants in the Breast Cancer Information Core (BIC), ClinVar and BRCA Share databases are VUS (3–5).

Spliceogenic variants are probably the most challenging for the geneticists as each nucleotide variation, regardless of its location, can potentially affect pre-mRNA splicing and be pathogenic via disruption of 5' or 3' splice sites (5'/3' ss),

creation of new 5'/3' ss or alteration of splicing regulatory elements. It is estimated that ~15% of all point mutations causing human inherited disorders disrupt splice-site consensus sequences (6). Consequently, assessing the impact of variants on splicing is a mandatory task in molecular diagnosis. Toward this aim, several *in silico* prediction tools can be used either as stand-alone programs or as interfaces integrating multiple algorithms (see 'Materials and Methods' section). These tools are important to select variants that are worthy of expensive and time-consuming RNA analyses. This is why we published user's guidelines from the splice network of French *BRCA* diagnostic laboratories within the Unicancer Genetic Group hereinafter named UGG, (<http://www.unicancer.fr/en/unicancer-group>) (7), recommending the combined use of two bioinformatics variation scores MaxEntScan (MES) and Splice Site Finder-like (SSF-like) between the mutated and wild-type (WT) sequences. Two thresholds of relative decrease of scores at 15% for MES and 5% for SSF-like permitted to obtain a sensitivity of 96% and a specificity of 83%. While useful, these guidelines are prone to false-negative predictions (see below, 'Results' section) and could therefore be improved. Consequently, we developed a new prediction tool, called Splicing Predictions in Consensus Elements (SPiCE), to prioritize RNA studies to relevant variants that alter 5' and 3' splice consensus regions i.e. 11 bases for the 5' splice site and 14 bases for the 3' splice site. SPiCE uses logistic regression by running different combinations of *in silico* tools. Thanks to an international collaborative effort including the ENIGMA consortium (evidence-based network for the interpretation of germline mutant alleles, <https://enigmaconsortium.org/>) (8), we were able to collect 305 *BRCA1* and *BRCA2* variants occurring in 5' and 3' consensus regions with their corresponding splice study. SPiCE was developed using a training set of 142 *BRCA1* and *BRCA2* variants and validated on a further set of 163 *BRCA1* and *BRCA2* splice variants. Furthermore, and to demonstrate its versatility, SPiCE was successfully applied to another set of 90 variants occurring in 5' and 3' consensus regions of 9 non-cancer genes e.g. in *CFTR* (MIM#602421), *CTRC* (MIM#601405), *HFE* (MIM#613609), *HJV* (MIM#608374), *LRP5* (MIM#603506), *PDK1* (MIM#602524), *RHD* (MIM#111690), *SLC40A1* (MIM#604653) and *TFR2* (MIM#604250).

MATERIALS AND METHODS

Nomenclature

Nucleotide numbering is based on the cDNA sequence of *BRCA1*, *BRCA2*, *CFTR*, *CTRC*, *HFE*, *HJV*, *LRP5*, *PKD1*, *RHD*, *SLC40A1*, *TFR2* (NCBI accession number NM_007294.2, NM_000059.3, NM_000492.3, NM_007272.2, NM_000410.3, NM_213653.3, NM_002335.3, NM_001009944.2, NM_016124.4, NM_014585.5, NM_003227.3, respectively), c.1 denoting the first nucleotide of the translation initiation codon, as recommended by the Human Genome Variation Society.

Definition of consensus splice site regions

Consensus splice site regions (5'ss and 3'ss) were defined according to Burge *et al.*, (9), i.e. 11 bases for the 5' splice site (from the 3 last exonic to the 8 first intronic bases) and 14 bases for the 3' splice site (from the 12 last intronic to the first 2 exonic bases).

Datasets

Among this initiative, 395 variants occurring in the consensus 5'/3' ss regions of 11 genes were collected, along with their respective RNA studies, and distributed between a training set and a validation set (Figure 1).

The training set (Supplementary Table S1) comprises 142 *BRCA1* and *BRCA2* variants from the UGG network. We performed transcript analyses as previously described (7). Briefly, protocols for transcript analyses included (i) minigene-based splicing assays, (ii) RNA extracted from lymphoblastoid cell lines treated/untreated with puromycin, (iii) RNA extracted from blood collected into PAXgene tubes (Qiagen), (iv) RNA extracted from stimulated T lymphocytes. Controls (samples without variant) were always included in these experiments. No discordance was observed between *in vitro* studies for the same variants.

To validate the SPiCE tool, we first gathered from the literature 208 transcript analyses from 163 distinct *BRCA1* ($n = 92$) and *BRCA2* ($n = 71$) variants reported in 56 publications. This curated collection of information was provided by members of the ENIGMA consortium as part of an ongoing data collection used for variant review (10,11) (Supplementary Table S2). Twelve of them (denoted by cross (†) in Supplementary Table S2) were analyzed at least twice and splicing alteration was constantly observed for 11 variants, with outcomes for different variants including exon skipping, use of cryptic splice site or combination of these events. Only one variant (c.518G>T in *BRCA2*) had contradictory reported and the reasons for this discordance remain unknown (12,13). Second, to extend the use of SPiCE to non-*BRCA*-genes, the second set of validation comprised 90 variants on *CFTR* ($n = 44$), *CTRC* ($n = 2$), *HFE* ($n = 1$), *HJV* ($n = 1$), *LRP5* ($n = 1$), *PKD1* ($n = 1$), *RHD* ($n = 38$), *SLC40A1* ($n = 1$) and *TFR2* ($n = 1$) with their splicing effect evaluated by minigene assay (Supplementary Table S3) (14). These variants were identified during the course of genetic counseling and thereby reflect clinical practice.

In silico tools

Five *in silico* prediction tools were tested: MES, (http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html) (15), SSF (16), Human Splicing Finder (HSF) (<http://www.umd.be/HSF3/>) (17), Neural Network Splice (NNS) (http://www.fruitfly.org/seq_tools/splice.html) (18) and GeneSplicer (GS) (http://www.cbcb.umd.edu/software/GeneSplicer/gene_spl.shtml) (19). Very briefly, the calculation of an MES score is based on maximum entropy of a nucleotide sequence with a set of constraints fixed by the MES model, including the variant's neighboring bases. NNS also takes into account the variant's neighboring position, but unlike MES, NNS is based on a machine

learning technique i.e. artificial neural networks. For SSF and HSF, the score calculation is based on a position weight matrix and its homologous percentage with the tested sequence. We used SSF-like, a version of SSF, allowing calculation score of donor splice site with GT and GC canonical motifs, embedded in Alamut[®] and in SPiCE. At last, GS is based on a decision tree method. It captures potential strong dependencies between signal positions by dividing the dataset into subsets based on pairwise dependency between positions and modeling each subset separately (20). The outcomes of each of these tools were simultaneously obtained by using the commercial software (Alamut[®] Visual software version 2.8 rev. 1 and Alamut[®] Batch version 1.5.2., Interactive Biosoftware).

Logistic regression and model definition

First, we processed to descriptive analysis of bioinformatic prediction scores. We tested the discriminant capacity of these scores by receiver-operating characteristics (ROC) curves, representing the sensitivity as a function of 1-specificity (21), using the R package ROCR (22) and the correlation between variables by Pearson's coefficient. Then, we used logistic regression to estimate the probability that a variant alters splicing. Parameter values were obtained by maximum likelihood, as objective function. This model was implemented in R software version 3.3.1 with the generalized linear model (glm) function. We considered that splicing alterations could correspond either to abnormal splicing events or to reinforcement of alternative splicing with partial or total effect. Splice event can be a single or multiple exon skipping and the use of exonic or intronic cryptic 5' or 3' splice sites. Selected variables to explain splicing alteration by a variant were (i) variation of prediction scores between WT and variant sequences, defined by Equation (1) and the score was annotated Δ MES, Δ SSF, Δ HSF, Δ NNS or Δ GS, (ii) localization in the invariant splice site positions (3'AG/5'GT), (iii) donor (5') or acceptor (3') splice sites, (iv) genes (e.g.: *BRCA1* or *BRCA2*).

$$\Delta \text{score} = \frac{\text{score}_{\text{mutated}} - \text{score}_{\text{wt}}}{\text{score}_{\text{wt}}} \quad (1)$$

To construct our final model we used a selection procedure based on a stepwise type approach with Akaike Information Criterion (AIC). Thereby AIC allows us to consider the likelihood of our model and the number of parameters in order to have the best model with a minimum of parameters. Models were compared by a likelihood ratio test. Cross-validation and other validation steps of the final model are described in the Supplementary Methods. AIC was considered more relevant than the Bayesian Information Criterion for a predictive approach. In any case, the two different criteria provided similar values (see Supplementary Table S7).

We developed SPiCE software, in the commonly utilized 'R' language to enable it to be freely applicable, information on this software are in Supplementary Material (see SPiCE handbook supplementary document). This software generates MES and SSF-like scores. For this purpose, the MES script was retrieved from the BurgeLab website (see *in silico* tools) and the SSF-like script was rewritten for SPiCE in




Figure 1. Curated datasets and *in vitro* analyses methods used in this study.

R language according to its description under the original publication (16) and under the manual of the commercial Alamut software. Position weight matrices, used by SSF-like for scoring acceptor and donor splice sites, were obtained from SpliceDB which contains 28 468 pairs of splice site sequences (23).

***In silico* predictions using previously published guidelines**

In order to compare SPiCE with our former guidelines, the *BRCA1/2* validation set was assayed as previously described (7).

RESULTS

Aberrant splicing events were described for each dataset in Supplementary Table S4. Briefly we observed 76.7% (303/395) variants that alter splicing, with 44.6% of exon skipping, 10.9% use of 5' alternative splice sites, 8.9% use of 3' alternative splice site and 12.4% of multiple aberration.

***BRCA1/BRCA2* training set**

In total we performed 188 *in vitro* analyses on 142 variants including 37 unpublished variants on both *BRCA1* (21 variants) and *BRCA2* (16 variants). The variants from the training set were equally distributed between *BRCA1* and *BRCA2* genes, 50.7% (72/142) and 49.3% (70/142), respectively. Eighty-four variants (60%) were localized at the prox-

imity of the 5' ss and the 58 (40%) remainder at the proximity of the 3' ss. Ninety-five variants altered splicing and were mainly (54.7%, 52/95) located outside the AG/GT dinucleotides (Table 1 and Figure 2A).

***BRCA1/BRCA2* validation set**

In the 163 variants collected from the literature, 92 (56.4%) variants were in *BRCA1* and 71 variants in *BRCA2*. These variants were mainly localized on the donor sites compared to the acceptor sites, 58.3% (94/163) and 41.7% (69/163), respectively. Sixty of 135 (44.4%) variants that alter splicing were outside canonical dinucleotides (Table 1 and Figure 2B).

Non-*BRCA* validation set

We also selected 90 variants in nine non-*BRCA* genes, which were in *CFTR* ($n = 44$), *CTRC* ($n = 2$), *HFE* ($n = 1$), *HJV* ($n = 1$), *LRP5* ($n = 1$), *PKD1* ($n = 1$), *RHD* ($n = 38$), *SLC40A1* ($n = 1$) and *TFR2* ($n = 1$) (Supplementary Table S3). Fifty-three variants (58.9%) were in donor splice sites and 37 (41.1%) in acceptor sites. Seventy-three variants altered splicing in minigene assays. Half of these ($n = 36$; 49.3%) are in the AG/GT dinucleotides (Table 1 and Figure 2C). Some positions were poorly represented and this uneven distribution outside 5'/3' ss can explain the imbalance between variants that do and do not affect splicing, 73 and 17 variants, respectively (Figure 2C).




Figure 2. Localization and impact of variants according to distance from splice site. X-axis: variant altering splicing (black bar), variant without effect (gray bar). Y-axis: total number of variants for each position. Donor and acceptor splice sites were defined as -3 nt in exon to $+8$ nt in intron and -12 nt in intron to $+2$ nt in exon, respectively. (A) variants from training set. (B) variants from *BRCA1/BRCA2* validation set. One single base deletion that affects the canonical AG splice site does not induce aberrant splicing. The reason is that the deletion removes a 'A' from the canonical 'AG' but without disrupting the consensus as the following neighboring nucleotide is another 'A' which in turn does preserve the consensus (C) variants from other genes validation set.

Descriptive analyses of bioinformatics prediction score

To determine if prediction scores from different algorithms give similar information or not on our training set, we calculated Pearson coefficient correlation for each algorithm. The greatest correlations were between HSF and SSF-like (0.80) and between MES and NNS (0.87). GS score has the lowest correlation with the other prediction scores (ranging from 0.43 to 0.48). Excluding GS score, the lowest values were observed between SSF-like and MES (0.71) and between NNS and HSF (0.60) (Supplementary Table S5). The predictive capacity of each algorithm was measured by ROC curves. NNS and GS scores have the lowest area under the curve (AUC) values (0.907 and 0.736, respectively). MES and SSF-like scores have the best and similar AUC

value (0.968 and 0.952, respectively) (Figure 3). As a result, MES and SSF-like provide high predictive capacity with distinct information.

Model definition of SPiCE

Since our last large study in 2012 (7), we collected and analyzed in the UGG network a new set of 51 variants (37 unpublished variants). We applied our previous guidelines to identify variant that alter splicing and obtained a sensitivity equal to 74.3% (26/35), prompting us to develop SPiCE (Supplementary Table S6).

First, we performed univariate analysis for each variable (variation of prediction scores, localization in the invariant regions, donor (5') or acceptor (3') splice sites, genes). We

Table 1. Distribution of variants in training and validation sets (n = 395)

No. (%) of variants			No. (%) of variants altering splicing		
5'/3' splice site			5'/3' splice site		
Gene	5'	3'	Gene	5'	3'
Training set, n = 142 variants			n = 95 variants altering splicing		
<i>BRCA1</i>	42 (58.3)	30 (41.7)	<i>BRCA1</i>	32 (66.7)	16 (33.3)
<i>BRCA2</i>	42 (60.0)	28 (40.0)	<i>BRCA2</i>	32 (68.1)	15 (31.9)
Total	84 (59.2)	58 (40.8)	Total	64 (67.4)	31 (32.6)
<i>BRCA1/BRCA2 validation set, n = 163</i>			n = 135 variants altering splicing		
<i>BRCA1</i>	54 (58.7)	38 (41.3)	<i>BRCA1</i>	49 (64.5)	27 (35.5)
<i>BRCA2</i>	40 (56.3)	31 (43.7)	<i>BRCA2</i>	36 (61.0)	23 (39.0)
Total	94 (57.7)	69 (42.3)	Total	85 (63.0)	50 (37.0)
<i>Non-BRCA validation set, n = 90</i>			n = 73 variants altering splicing		
<i>CFTR</i>	23 (52.3)	21 (47.7)	<i>CFTR</i>	23 (60.5)	15 (39.5)
<i>RHD</i>	26 (68.4)	12 (31.6)	<i>RHD</i>	22 (73.3)	8 (26.7)
Other genes ^a	4 (50.0)	4 (50.0)	Other genes ^a	3 (60.0)	2 (40.0)
Total	53 (58.9)	37 (41.1)	Total	48 (65.8)	25 (34.2)

^a: LRP5, CTSC, HFE, HJV, PKD1, SLC40A1, TFR2.




Figure 3. ROC curves of different bioinformatics scores from the training set (n = 142). GS: GeneSplicer; HSF: Human splicing finder; MES: MaxEntScan; NNS: Neural network splice; SSF: SpliceSite finder.

Table 2. Model parameters

Parameters	Value	P-value of Wald's test
β_0	-3.59	5.48 ^e -6
β_{MES}	-8.21	4.28 ^e -3
β_{SSF}	-32.30	6.37 ^e -3

β_0 : Intercept; β_{MES} : Parameter of MES score; β_{SSF} : Parameter of SSF-like score.

observed that MES had a better Akaike Information Criterion (AIC) than the other variables (63.46) (Supplementary Table S7). Then, we performed multivariate analysis by adding other variables to MES. We found that only the combination of MES and SSF-like significantly improved the AIC with *P*-value of likelihood ratio test under 5% (Supplementary Table S7). The values for intercept, MES and SSF-like parameters are shown in Table 2. These three parameters were significantly different from 0 (*P*-value of Wald's test < 0.05). Taken into account that MES and SSF-like do not score +7 and +8 position of the 5'ss, SPiCE should not be used at these positions.

We determined our thresholds by using ROC curve analyses on the training set (Figure 4A). The aim of these thresholds is to prioritize *in vitro* RNA studies of variants. Two probability thresholds were thus defined: optimal sensitivity threshold (Th_{Se}) and optimal specificity threshold (Th_{Sp}), 0.115 and 0.749, respectively. As sensitivity is defined as the ratio of true positives divided by the sum of true positives and false negatives, Th_{Se} is designed to give the highest detection rate while allowing false positives. On the other hand, specificity is the ratio of true negatives divided by the sum of true negatives and false positives, meaning Th_{Sp} is designed to minimize false positives while allowing false negatives. Sensitivity and specificity with Th_{Se} are 100% (95/95) and 74.5% (35/47), respectively. Sensitivity and specificity with Th_{Sp} are 88.4% (84/95) and 95.7% (45/47), respectively. In both cases, accuracy was equal to 90.8% (data not shown). Our bootstrap analysis (Supplementary Table S8 and Figure S1) confirmed stability of model parameters and thresholds. We observed that cross-validation confirmed the pertinence of combined MES and SSF-like variation scores relative to the variation scores of MES or SSF-like alone (Supplementary Table S9 and Figure S2).

SPiCE performances on the *BRCA1* and *BRCA2* validation set

Following definition and training, SPiCE was validated on two independent sets of splice data. For each variant, the probability to have a splice effect was calculated and outcomes were predicted according to the previously determined thresholds (Table 3). To facilitate users' interpretation, a graphical view was developed where decision thresholds are traced and variants spotted according to their values of their SSF-like and MES score variation (Figure 5). In-between thresholds, the area is thereby defined as the 'gray area' that includes only 16/160 variants. Optimal sensitivity threshold gave 99.3% sensitivity (134/135) and 68.0% (17/25) specificity. Optimal specificity threshold gave 92.6% sensitivity (125/135) and 92.0% (23/25) specificity

(Figure 4B). Accuracy values were 94.4% (151/160) and 92.5% (148/160) for Th_{Se} and Th_{Sp} , respectively, i.e. above accuracy obtained on the training set (90.8%).

To further assess SPiCE efficiency, we compared the proportion of variants that affect splicing with their average SPiCE probability. Hence we subdivided our validation sets into groups according to their SPiCE probability. Ideally, the proportion of variants that affect splicing in any given group should be equal to the average SPiCE probability in this group. This is the case for our SPiCE model except for 4% (10/250) of variants with a probability between 0.115 and 0.432 (Supplementary Figure S3).

Then we studied a possible association between prediction accuracy and distance to canonical splice site (AG/GT). As shown in Supplementary Figure S4, SPiCE remains accurate throughout the consensus regions, even in the less conserved parts. However, we noted higher variability for polypyrimidine tract of 3' ss (from -5 to -12).

SPiCE performances on the non-*BRCA* validation set

For *CFTR* and *RHD* for which we tested more than 35 variants, and 7 other genes for which we tested a few variants, SPiCE classification using Th_{Se} gave a 100% sensitivity and a 82.3% specificity. Th_{Sp} gave 91.7% sensitivity and 100% specificity (Table 3 and Figure 4C). Combination of two thresholds of SPiCE protocol did not result in misclassified variants (0 false positive and 0 false negative). These results confirmed that the SPiCE protocol is pertinent in non-*BRCA* genes.

SPiCE performances with previous published guideline

We compared the performance of our previously published guidelines to SPiCE on validation sets, $n = 250$ (Table 4). Using Th_{Sp} , SPiCE improves the specificity to 95.2% (40/42) against 83% with previous guidelines whereas with Th_{Se} SPiCE dramatically decreases the number of false negatives from 14 to 1 variant i.e. a sensitivity equals to 99.5%.

Further quantitative aspects

We questioned the capability of SPiCE to predict the quantitative nature of the splice anomalies. To this aim, 232 analyses for which the semi-quantitative effect was known were selected from the training set and the non-*BRCA* validation set. These 232 analyses were for diagnostic purposes and the semi quantitative effect was taken into account for patient's reporting. As a result, and despite the well-known difficulties in splice quantification, these data were considered reliable. Semi-quantitative effect was defined using the previously published classes i.e. 1S (no effect on splicing), 2S (partial effect) and 3S (complete effect) (7) and plotted against SPiCE probabilities (Supplementary Figure S5). A trend emerged as some partial effects led to lower probabilities as compared to complete effects but we were not able to define a prediction threshold between low/high intensity effects.




Figure 4. ROC curve of the SPiCE logistic regression model. **(A)** on training set ($n = 142$), $AUC = 0.986$. **(B)** On *BRCA1* and *BRCA2* validation set ($n = 160$), $AUC = 0.969$. **(C)** On other genes validation set ($n = 90$), $AUC = 0.989$. Arrows correspond to decision thresholds for optimal sensitivity (0.115) and optimal specificity (0.749).




Figure 5. SPiCE graphical output results on *BRCA1/BRCA2* validation set ($n = 160$). Representation of variants according to their SSF-like and MES scores variations in percentage. Blue area represents variants with probability of splicing alteration under decision threshold of optimal sensitivity, red area corresponds to probability upper decision threshold of optimal specificity and gray area is probability between these two thresholds. Blue points are variants without splicing effect and red points are variants altering splicing.

Table 3. SPiCE spliceogenicity prediction of variants in validation sets ($n = 160$ and $n = 90$)

	<i>BRCA1</i> and <i>BRCA2</i> validation set		Other genes validation set	
	With alteration	Without alteration	With alteration	Without alteration
$P > Th_{Sp}$	125	2	67	0
$Th_{Sp} < P < Th_{Se}$	9	6	6	3
$P < Th_{Se}$	1	17	0	14

P: Probability of variant to have splicing alteration; Th_{Se} : Optimal sensitivity threshold; Th_{Sp} : Optimal specificity threshold.

Table 4. Contingency table on validation datasets (*BRCA1/2* and other genes, ($n = 250$) with guidelines of Houdayer and coll (7)

	With alteration	Without alteration
$\Delta\text{MES} > 15\%$ and $\Delta\text{SSF} > 5\%$	194	4
$\Delta\text{MES} < 15\%$ or $\Delta\text{SSF} < 5\%$	14	38

DISCUSSION

General considerations

This international effort represents the largest *in silico* study of splice variants with their corresponding *in vitro/ex vivo* transcript analyses conducted to date by a consortium. These international initiatives are needed to get results of wide scale relevance i.e. for the whole community. It enabled us to build SPiCE, a powerful prediction tool for variants occurring at splice site consensus regions, based on combination of MES and SSF-like by logistic regression. The reason is that among the five algorithms tested (GS, HSF, MES, NNS, SSF-like), we found that SSF-like and MES provide the best prediction on splicing effect of variants, as previously suggested by our group and others (24). Logistic regression analysis allows us to outperformed use of bioinformatics score variations of MES and SSF-like alone. SPiCE fulfills all the necessary criteria for model validation, e.g. stability of model, without bias. It has been validated on two replicative sets including 11 different genes and developed in the commonly utilized ‘R’ language to ensure free and wide access.

SPiCE performs with high accuracy (95.6%) and sensitivity (99.5%) throughout the consensus sequences. The sole apparent false negative identified on *BRCA1* and *BRCA2* variants was c.5408G>C in the *BRCA1* gene that leads to exon 23 skipping. The reason for this false-negative may be due to the complexity of splicing control i.e. due to another mechanism, such as the disruption of distal auxiliary splicing regulatory elements. This alternative explanation could be proven by dedicated minigene assays (12,25,26). Not surprisingly, there is a need for complementary prediction tools to complete our predictions and a fully comprehensive tool will eventually emerge from the combination of SPiCE and promising splicing regulatory element predictions (25,27,28). Moreover, by embedding comprehensive tools for exon definition, we would in turn be able to distinguish real exons from pseudoexons (29). Thanks to this international network of laboratories, these novel developments are planned to address this challenge.

Recommendations for routine analyses

SPiCE allows the user to know the risk of missing a true splice alteration according to the probability calculated. As sensitivity is a key issue in molecular diagnosis, we would recommend using the optimal sensitivity threshold (Th_{Se} , probability above 0.115, i.e. including ‘gray area’) which in our hands gave only one false negative for *BRCA1* while also a limiting number of false positives. On the other hand, depending on laboratory resources, the user can rely on the optimal specificity threshold (Th_{Sp} , probability above 0.749)

which keeps false positives to a minimum as we observed only two false positives out of 42 variants without splice effect in our validation sets.

Previous prediction methods have been proposed for identifying variants that likely alter splicing. However, these methods were defined on small series thereby limiting their applicability (30–35). A recent work (36) on a large series of 272 variants in consensus regions suggested the use of a MES threshold of relative decrease of 10%, however this threshold leads to a specificity of 50% (21/42) on our validation datasets. The UGG network previously published a large series of splicing variants and accompanying guidelines for *in silico* predictions (7). Importantly SPiCE outperforms our previous results as demonstrated on the validation sets of variants from *BRCA1*, *BRCA2* and other genes (Tables 3 and 4).

At this point in time, SPiCE predicts potential splicing alteration of variants at 5' and 3' ss but neither the type of the effect (exon skipping or use of alternative splice site) nor the importance of the effect (partial or total) are predicted, although the tool is able to detect a trend in the prediction severity of splicing defects (Supplementary Figure S5). This trend would allow to prioritize assays for those VUS predicted to have more severe effects on mRNA splicing. Importantly enough, SPiCE can be used beyond *BRCA1* and *BRCA2* and applied to other genes to guide geneticists in their daily practice. The majority of non-*BRCA* variants comes from two different genes (*CFTR* and *RHD*) but this should not create a bias as SPiCE runs MES and SSF which have been trained on our 20 000 protein-coding genes. Moreover we believe SPiCE versatility is demonstrated by testing these non-cancer genes i.e. involved in distinct pathways. This versatility is of special relevance as issues on misinterpretations and/or conflicting interpretations impact all fields of genetic diagnosis, leading to difficult situations for patients but also for health professionals. Given that 25% of clinical genetic results from commercial cancer panels had conflicting interpretation in ClinVar, the variant interpretation challenge is prone to erroneous medical decisions and eventually lawsuit as shown in Dravet syndrome (37). Without doubt, the development of reliable *in silico* tools is a major improvement toward reliable variant classification and patient's management.

Overall, SPiCE has the potential of a widely used decision-making tool to guide geneticists toward relevant spliceogenic variants in the deluge of high-throughput sequencing data.

DEDICATION

This work is dedicated to the memory of our colleague Olga Sinilnikova.

DATA AVAILABILITY

SPiCE software is available at (<https://sourceforge.net/projects/spicev2-1/>).

SUPPLEMENTARY DATA

Supplementary Data are available at NAR Online.

ACKNOWLEDGEMENTS

The authors wish to thank Valentin Harter for biostatistics analysis advices and Emma Tudini for gathering data from the literature.

FUNDING

NHMR Senior Research Fellowship [ID1061779 to A.B.S.]; The Cancer Council Queensland [ID1086286 to M.P., in part]; French National Cancer Institute Translational Research Grant; Direction Générale de l'Offre des Soins (INCa/DGOS). Funding for open access charge: Laboratoire de Biologie et Génétique du Cancer; Centre François Baclesse, Caen, France.

Conflict of interest statement. None declared.

REFERENCES

- Plon, S.E., Eccles, D.M., Easton, D., Foulkes, W.D., Genuardi, M., Greenblatt, M.S., Hogervorst, F.B.L., Hoogerbrugge, N., Spurdle, A.B. and Tavtigian, S.V. (2008) Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. *Hum. Mutat.*, **29**, 1282–1291.
- Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W.W., Hegde, M., Lyon, E., Spector, E. *et al.* (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet. Med.*, **17**, 405–423.
- Caputo, S., Benboudjema, L., Sinilnikova, O., Rouleau, E., Bérout, C. and Lidereau, R. (2012) Description and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-BRCA1/BRCA2 databases. *Nucleic Acids Res.*, **40**, D992–D1002.
- Landrum, M.J., Lee, J.M., Riley, G.R., Jang, W., Rubinstein, W.S., Church, D.M. and Maglott, D.R. (2014) ClinVar: public archive of relationships among sequence variation and human phenotype. *Nucleic Acids Res.*, **42**, D980–D985.
- Szabo, C., Masiello, A., Ryan, J.F. and Brody, L.C. (2000) The breast cancer information core: database design, structure, and scope. *Hum. Mutat.*, **16**, 123–131.
- Baralle, D., Lucassen, A. and Buratti, E. (2009) Missed threads. *EMBO Rep.*, **10**, 810–816.
- Houdayer, C., Caux-Moncoutier, V., Krieger, S., Barrois, M., Bonnet, F., Bourdon, V., Bronner, M., Buisson, M., Coulet, F., Gaildrat, P. *et al.* (2012) Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variants. *Hum. Mutat.*, **33**, 1228–1238.
- Spurdle, A.B., Healey, S., Devereau, A., Hogervorst, F.B.L., Monteiro, A.N.A., Nathanson, K.L., Radice, P., Stoppa-Lyonnet, D., Tavtigian, S., Wappenschmidt, B. *et al.* (2012) ENIGMA—Evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. *Hum. Mutat.*, **33**, 2–7.
- Burge, C.B., Tuschli, T. and Sharp, P.A. (1999) Splicing of precursors to mRNAs by the spliceosomes. In: *The RNA World II*. Cold Spring Harbor Laboratory Press; Oxford University Press, NY, pp. 525–560.
- Vallée, M.P., Di Sera, T.L., Nix, D.A., Paquette, A.M., Parsons, M.T., Bell, R., Hoffman, A., Hogervorst, F.B.L., Goldgar, D.E., Spurdle, A.B. *et al.* (2016) Adding in silico assessment of potential splice aberration to the integrated evaluation of BRCA gene unclassified variants. *Hum. Mutat.*, **37**, 627–639.
- Walker, L.C., Whiley, P.J., Houdayer, C., Hansen, T.V.O., Vega, A., Santamarina, M., Blanco, A., Fachal, L., Southey, M.C., Lafferty, A. *et al.* (2013) Evaluation of a 5-Tier scheme proposed for classification of sequence variants using bioinformatic and splicing assay data: inter-reviewer variability and promotion of minimum reporting guidelines. *Hum. Mutat.*, **34**, 1424–1431.
- Di Giacomo, D., Gaildrat, P., Abuli, A., Abdat, J., Frébourg, T., Tosi, M. and Martins, A. (2013) Functional analysis of a large set of BRCA2 exon 7 variants highlights the predictive value of hexamer scores in detecting alterations of exonic splicing regulatory elements. *Hum. Mutat.*, **34**, 1547–1557.
- Sanz, D.J., Acedo, A., Infante, M., Durán, M., Pérez-Cabornero, L., Esteban-Cardena, E., Lastra, E., Pagani, F., Miner, C. and Velasco, E.A. (2010) A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in Breast/Ovarian cancer patients. *Clin. Cancer Res.*, **16**, 1957–1967.
- Callebaut, I., Joubrel, R., Pissard, S., Kannengiesser, C., Gérolami, V., Ged, C., Cadet, E., Cartault, F., Ka, C., Gourlaouen, I. *et al.* (2014) Comprehensive functional annotation of 18 missense mutations found in suspected hemochromatosis type 4 patients. *Hum. Mol. Genet.*, **23**, 4479–4490.
- Yeo, G. and Burge, C.B. (2004) Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. *J. Comput. Biol.*, **11**, 377–394.
- Shapiro, M.B. and Senapathy, P. (1987) RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. *Nucleic Acids Res.*, **15**, 7155–7174.
- Desmet, F.-O., Hamroun, D., Lalande, M., Collod-Bérout, G., Claustres, M. and Bérout, C. (2009) Human splicing finder: an online bioinformatics tool to predict splicing signals. *Nucleic Acids Res.*, **37**, e67–e67.
- Reese, M.G. and Eeckman, F.H. (1995) Novel neural network prediction systems for human promoters and splice sites. In: Searls, G.S.D., Fickett, J. and Noordewier, M. (eds). *Gene-Finding and Gene Structure Prediction Workshop*. Philadelphia, PA, 1–7.
- Perte, M., Lin, X. and Salzberg, S.L. (2001) GeneSplicer: a new computational method for splice site prediction. *Nucleic Acids Res.*, **29**, 1185–1190.
- Jian, X., Boerwinkle, E. and Liu, X. (2014) In silico tools for splicing defect prediction: a survey from the viewpoint of end users. *Genet. Med.*, **16**, 497–503.
- Zweig, M.H. and Campbell, G. (1993) Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. *Clin. Chem.*, **39**, 561–577.
- Sing, T., Sander, O., Beerenwinkel, N. and Lengauer, T. (2005) ROCr: visualizing classifier performance in R. *Bioinformatics*, **21**, 3940–3941.
- Burset, M., Seledtsov, I.A. and Solovyev, V.V. (2001) SpliceDB: database of canonical and non-canonical mammalian splice sites. *Nucleic Acids Res.*, **29**, 255–259.
- Jian, X., Boerwinkle, E. and Liu, X. (2014) In silico prediction of splice-altering single nucleotide variants in the human genome. *Nucleic Acids Res.*, **42**, 13534–13544.
- Ke, S., Anquetil, V., Zamalloa, J.R., Maity, A., Yang, A., Arias, M.A., Kalachikov, S., Russo, J.J., Ju, J. and Chasin, L.A. (2018) Saturation mutagenesis reveals manifold determinants of exon definition. *Genome Res.*, **28**, 11–24.
- Lee, Y. and Rio, D.C. (2015) Mechanisms and regulation of alternative Pre-mRNA splicing. *Annu. Rev. Biochem.*, **84**, 291–323.
- Soukarieh, O., Gaildrat, P., Hamieh, M., Drouet, A., Baert-Desurmont, S., Frébourg, T., Tosi, M. and Martins, A. (2016) Exonic splicing mutations are more prevalent than currently estimated and can be predicted by using in silico tools. *PLoS Genet.*, **12**, e1005756.
- Julien, P., Miñana, B., Baeza-Centurion, P., Valcárcel, J. and Lehner, B. (2016) The complete local genotype–phenotype landscape for the alternative splicing of a human exon. *Nat. Commun.*, **7**, 11558–11566.
- Chasin, L.A. (2007) Searching for splicing motifs. *Adv. Exp. Med. Biol.*, **623**, 85–106.
- Holla, Ø.L., Nakken, S., Mattingsdal, M., Ranheim, T., Berge, K.E., Defesche, J.C. and Leren, T.P. (2009) Effects of intronic mutations in the LDLR gene on pre-mRNA splicing: Comparison of wet-lab and bioinformatics analyses. *Mol. Genet. Metab.*, **96**, 245–252.
- Houdayer, C., Dehainault, C., Mattler, C., Michaux, D., Caux-Moncoutier, V., Pagès-Berhouet, S., d'Enghien, C.D., Laugé, A., Castera, L., Gauthier-Villars, M. *et al.* (2008) Evaluation of in silico splice tools for decision-making in molecular diagnosis. *Hum. Mutat.*, **29**, 975–982.
- Théry, J.C., Krieger, S., Gaildrat, P., Révillion, F., Buisine, M.-P., Killian, A., Duponchel, C., Rousselin, A., Vaur, D., Peyrat, J.-P. *et al.* (2011) Contribution of bioinformatics predictions and functional

- splicing assays to the interpretation of unclassified variants of the BRCA genes. *Eur. J. Hum. Genet.*, **19**, 1052–1058.
33. Vreeswijk, M.P.G., Kraan, J.N., van der Klift, H.M., Vink, G.R., Cornelisse, C.J., Wijnen, J.T., Bakker, E., van Asperen, C.J. and Devilee, P. (2009) Intronic variants in BRCA1 and BRCA2 that affect RNA splicing can be reliably selected by splice-site prediction programs. *Hum. Mutat.*, **30**, 107–114.
34. Whiley, P.J., Guidugli, L., Walker, L.C., Healey, S., Thompson, B.A., Lakhani, S.R., Da Silva, L.M. and Investigators, kConFab (2011) Splicing and multifactorial analysis of intronic BRCA1 and BRCA2 sequence variants identifies clinically significant splicing aberrations up to 12 nucleotides from the intron/exon boundary. *Hum. Mutat.*, **32**, 678–687.
35. Wimmer, K., Roca, X., Beiglböck, H., Callens, T., Etzler, J., Rao, A.R., Krainer, A.R., Fonatsch, C. and Messiaen, L. (2007) Extensive in silico analysis of NF1 splicing defects uncovers determinants for splicing outcome upon 5' splice-site disruption. *Hum. Mutat.*, **28**, 599–612.
36. Tang, R., Prosser, D.O. and Love, D.R. (2016) Evaluation of bioinformatic programmes for the analysis of variants within splice site consensus regions. *Adv. Bioinformatics*, **2016**, 10–20.
37. Levenson, D. (2017) Lawsuit raises questions about variant interpretation and communication. *Am. J. Med. Genet.*, **173**, 838–839.